SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Pharmalabs - Quaterly Results

10 May 2025 Evaluate
A decent increase of about 27.68% in the sales to Rs. 5296.24 millions was observed for the quarter ended March 2025. The sales figure stood at Rs. 4148.17 millions during the year-ago period.The company has announced a 40.98% increase in its profits to Rs . 888.46  millions for the  quarter ended March 2025 compared to Rs. 630.19 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 1406.22 millions compared to 1130.31 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 5296.24 4148.17 27.68 17713.52 15021.32 17.92 17713.52 15021.32 17.92
Other Income -25.05 56.88 -144.04 144.90 110.09 31.62 144.90 110.09 31.62
PBIDT 1406.22 1130.31 24.41 4410.34 3571.68 23.48 4410.34 3571.68 23.48
Interest 62.88 44.24 42.13 256.33 166.35 54.09 256.33 166.35 54.09
PBDT 1343.34 1086.07 23.69 4154.01 3405.33 21.99 4154.01 3405.33 21.99
Depreciation 208.31 173.24 20.24 790.59 660.14 19.76 790.59 660.14 19.76
PBT 1135.03 912.83 24.34 3363.42 2745.19 22.52 3363.42 2745.19 22.52
TAX 246.57 282.64 -12.76 789.92 738.74 6.93 789.92 738.74 6.93
Deferred Tax 98.16 165.67 -40.75 222.81 278.17 -19.90 222.81 278.17 -19.90
PAT 888.46 630.19 40.98 2573.50 2006.45 28.26 2573.50 2006.45 28.26
Equity 453.17 453.13 0.01 453.17 453.13 0.01 453.17 453.13 0.01
PBIDTM(%) 26.55 27.25 -2.56 24.90 23.78 4.71 24.90 23.78 4.71

Aarti Pharmalabs Share Price

693.75 4.75 (0.69%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×